Latest Insider Transactions at Esperion Therapeutics, Inc. (ESPR)
This section provides a real-time view of insider transactions for Esperion Therapeutics, Inc. (ESPR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Esperion Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Esperion Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 17
2025
|
Benjamin Halladay Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11
-0.0%
|
$11
$1.12 P/Share
|
|
Jul 17
2025
|
Benjamin Looker General Counsel |
SELL
Open market or private sale
|
Direct |
1,304
-0.33%
|
$1,304
$1.13 P/Share
|
|
Jun 17
2025
|
Benjamin Looker General Counsel |
SELL
Open market or private sale
|
Direct |
6,422
-1.58%
|
$6,422
$1.15 P/Share
|
|
Jun 17
2025
|
Benjamin Halladay Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,229
-1.5%
|
$7,229
$1.15 P/Share
|
|
Jun 17
2025
|
Sheldon L. Koenig President and CEO |
SELL
Open market or private sale
|
Direct |
30,474
-1.94%
|
$30,474
$1.11 P/Share
|
|
May 29
2025
|
Seth H. Z. Fischer Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,000
+35.05%
|
-
|
|
May 29
2025
|
J Martin Carroll Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,000
+25.26%
|
-
|
|
May 29
2025
|
Jay Shepard Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,000
+28.06%
|
-
|
|
May 29
2025
|
Stephen Rocamboli Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,000
+32.27%
|
-
|
|
May 29
2025
|
Robert E. Hoffman Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,280
+50.0%
|
-
|
|
Apr 17
2025
|
Benjamin Halladay Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8
-0.0%
|
$0
$0.96 P/Share
|
|
Apr 17
2025
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
108
-0.03%
|
$0
$0.98 P/Share
|
|
Mar 18
2025
|
Sheldon L. Koenig President and CEO |
SELL
Open market or private sale
|
Direct |
13,047
-0.82%
|
$13,047
$1.5 P/Share
|
|
Mar 18
2025
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,433
-0.65%
|
$2,433
$1.49 P/Share
|
|
Mar 18
2025
|
Benjamin Halladay Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,535
-0.73%
|
$3,535
$1.48 P/Share
|
|
Mar 14
2025
|
Benjamin Looker General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
224,000
+35.46%
|
-
|
|
Mar 14
2025
|
Eric Warren Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
213,000
+36.36%
|
-
|
|
Mar 14
2025
|
Benjamin Halladay Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
238,000
+32.91%
|
-
|
|
Mar 14
2025
|
Sheldon L. Koenig President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
840,000
+34.64%
|
-
|
|
Feb 19
2025
|
Benjamin Halladay Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11
-0.0%
|
$11
$1.86 P/Share
|
|
Feb 19
2025
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
239
-0.15%
|
$239
$1.87 P/Share
|
|
Jan 17
2025
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
123
-0.08%
|
$246
$2.26 P/Share
|
|
Jan 17
2025
|
Benjamin Halladay Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9
-0.0%
|
$18
$2.27 P/Share
|
|
Dec 17
2024
|
Sheldon L. Koenig President and CEO |
SELL
Open market or private sale
|
Direct |
12,447
-1.65%
|
$24,894
$2.47 P/Share
|
|
Dec 17
2024
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,234
-1.38%
|
$4,468
$2.43 P/Share
|
|
Dec 17
2024
|
Benjamin Halladay Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,245
-1.33%
|
$6,490
$2.42 P/Share
|
|
Nov 19
2024
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
197
-0.12%
|
$394
$2.17 P/Share
|
|
Oct 17
2024
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
107
-0.07%
|
$214
$2.12 P/Share
|
|
Sep 17
2024
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,608
-1.58%
|
$2,608
$1.78 P/Share
|
|
Sep 17
2024
|
Sheldon L. Koenig President and CEO |
SELL
Open market or private sale
|
Direct |
14,550
-1.9%
|
$14,550
$1.8 P/Share
|
|
Aug 19
2024
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
211
-0.13%
|
$211
$1.95 P/Share
|
|
Jul 17
2024
|
Joanne M. Foody Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
917
-0.33%
|
$1,834
$2.6 P/Share
|
|
Jul 17
2024
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
108
-0.07%
|
$216
$2.59 P/Share
|
|
Jun 18
2024
|
Joanne M. Foody Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,285
-1.19%
|
$6,570
$2.87 P/Share
|
|
Jun 18
2024
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,540
-1.51%
|
$5,080
$2.86 P/Share
|
|
May 23
2024
|
Jay Shepard Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+30.83%
|
-
|
|
May 23
2024
|
Stephen Rocamboli Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+38.81%
|
-
|
|
May 23
2024
|
Antonio M Jr Md D Phil Gotto Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+30.83%
|
-
|
|
May 23
2024
|
Alan Fuhrman Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+30.1%
|
-
|
|
May 23
2024
|
Seth H. Z. Fischer Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+44.97%
|
-
|
|
May 23
2024
|
J Martin Carroll Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+26.24%
|
-
|
|
May 17
2024
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
192
-0.11%
|
$384
$2.48 P/Share
|
|
Mar 14
2024
|
Eric Warren Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+37.27%
|
-
|
|
Mar 14
2024
|
Sheldon L. Koenig President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
454,000
+37.19%
|
-
|
|
Mar 14
2024
|
Benjamin Looker General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+35.25%
|
-
|
|
Mar 14
2024
|
Joanne M. Foody Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+35.12%
|
-
|
|
Mar 14
2024
|
Benjamin Halladay Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
170,000
+41.07%
|
-
|
|
Sep 20
2023
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
742
-1.07%
|
$742
$1.25 P/Share
|
|
Aug 18
2023
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
243
-0.35%
|
$243
$1.41 P/Share
|
|
Jul 19
2023
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
106
-0.15%
|
$106
$1.58 P/Share
|